Related Experiment Video
Updated: Jul 9, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Anti-TNF antibodies: lessons from the past, roadmap for the future
1Centocor Research and Development, Inc., 145 King of Prussia Road, Radnor, PA 19087, USA. dshealy@cntus.jnj.com
Monoclonal antibodies targeting tumor necrosis factor alpha (TNF) effectively reduce inflammation markers in immune-mediated diseases. These anti-TNF therapies also show benefits for bone and cartilage health, aiding patient treatment.
Area of Science:
- Immunology
- Pharmacology
Background:
- Tumor necrosis factor alpha (TNF) is a key immune system signaling molecule.
- Chronic inflammatory diseases like rheumatoid arthritis, Crohn's disease, and psoriasis are linked to TNF.
- Neutralizing monoclonal antibodies targeting TNF have been developed for therapeutic use.
Purpose of the Study:
- To evaluate the clinical efficacy of anti-TNF monoclonal antibodies.
- To assess the impact of anti-TNF treatment on inflammatory markers.
- To explore the effects of anti-TNF therapy on bone and cartilage turnover.
Main Methods:
- Clinical evaluation of patients treated with anti-TNF monoclonal antibodies (infliximab, adalimumab, certolizumab pegol).
- Measurement of localized and systemic markers of inflammation.
- Assessment of markers related to bone and cartilage turnover.
Main Results:
- Anti-TNF monoclonal antibody treatment significantly reduced markers of inflammation.
- Beneficial effects on bone and cartilage turnover markers were observed.
- Clinical and commercial data provide insights into the pharmacological effects of anti-TNF antibodies in humans.
Conclusions:
- Anti-TNF monoclonal antibodies offer substantial benefits for patients with chronic immune-mediated inflammatory diseases.
- Further research is needed to correlate changes in bone/cartilage markers with clinical efficacy for patient stratification.
- Extensive clinical and commercial experience highlights the pharmacological impact of these therapies.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cross-reactivity
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
